AstraZeneca PLC (Sweden) Performance
| AZN Stock | SEK 1,834 19.50 1.07% |
AstraZeneca PLC has a performance score of 7 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.34, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, AstraZeneca PLC's returns are expected to increase less than the market. However, during the bear market, the loss of holding AstraZeneca PLC is expected to be smaller as well. AstraZeneca PLC right now shows a risk of 1.45%. Please confirm AstraZeneca PLC semi variance, and the relationship between the maximum drawdown and accumulation distribution , to decide if AstraZeneca PLC will be following its price patterns.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in AstraZeneca PLC are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, AstraZeneca PLC may actually be approaching a critical reversion point that can send shares even higher in March 2026. ...more
| Begin Period Cash Flow | 6 B | |
| Free Cash Flow | 7.2 B |
AstraZeneca |
AstraZeneca PLC Relative Risk vs. Return Landscape
If you would invest 169,800 in AstraZeneca PLC on November 16, 2025 and sell it today you would earn a total of 13,650 from holding AstraZeneca PLC or generate 8.04% return on investment over 90 days. AstraZeneca PLC is generating 0.1414% of daily returns assuming 1.4529% volatility of returns over the 90 days investment horizon. Simply put, 13% of all stocks have less volatile historical return distribution than AstraZeneca PLC, and 98% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
AstraZeneca PLC Target Price Odds to finish over Current Price
The tendency of AstraZeneca Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1,834 | 90 days | 1,834 | near 1 |
Based on a normal probability distribution, the odds of AstraZeneca PLC to move above the current price in 90 days from now is near 1 (This AstraZeneca PLC probability density function shows the probability of AstraZeneca Stock to fall within a particular range of prices over 90 days) .
AstraZeneca PLC Price Density |
| Price |
Predictive Modules for AstraZeneca PLC
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as AstraZeneca PLC. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.AstraZeneca PLC Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. AstraZeneca PLC is not an exception. The market had few large corrections towards the AstraZeneca PLC's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold AstraZeneca PLC, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of AstraZeneca PLC within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.18 | |
β | Beta against Dow Jones | 0.34 | |
σ | Overall volatility | 43.23 | |
Ir | Information ratio | 0.1 |
AstraZeneca PLC Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of AstraZeneca PLC for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for AstraZeneca PLC can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| AstraZeneca PLC has accumulated 22.96 B in total debt with debt to equity ratio (D/E) of 0.87, which is about average as compared to similar companies. AstraZeneca PLC has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist AstraZeneca PLC until it has trouble settling it off, either with new capital or with free cash flow. So, AstraZeneca PLC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AstraZeneca PLC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AstraZeneca to invest in growth at high rates of return. When we think about AstraZeneca PLC's use of debt, we should always consider it together with cash and equity. |
AstraZeneca PLC Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of AstraZeneca Stock often depends not only on the future outlook of the current and potential AstraZeneca PLC's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. AstraZeneca PLC's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.5 B | |
| Dividends Paid | -4.4 B | |
| Short Long Term Debt | 5.3 B |
AstraZeneca PLC Fundamentals Growth
AstraZeneca Stock prices reflect investors' perceptions of the future prospects and financial health of AstraZeneca PLC, and AstraZeneca PLC fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AstraZeneca Stock performance.
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 2.49 T | |||
| Shares Outstanding | 1.55 B | |||
| Price To Earning | 437.97 X | |||
| Price To Book | 6.15 X | |||
| Price To Sales | 49.17 X | |||
| Revenue | 44.35 B | |||
| EBITDA | 9.33 B | |||
| Cash And Equivalents | 4.89 B | |||
| Cash Per Share | 3.15 X | |||
| Total Debt | 22.96 B | |||
| Debt To Equity | 0.87 % | |||
| Book Value Per Share | 23.91 X | |||
| Cash Flow From Operations | 9.81 B | |||
| Earnings Per Share | 22.08 X | |||
| Total Asset | 96.48 B | |||
| Retained Earnings | 8.07 B | |||
| Current Asset | 12.77 B | |||
| Current Liabilities | 15.93 B | |||
About AstraZeneca PLC Performance
Assessing AstraZeneca PLC's fundamental ratios provides investors with valuable insights into AstraZeneca PLC's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the AstraZeneca PLC is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. AstraZeneca PLC operates under Drug ManufacturersGeneral classification in Sweden and is traded on Stockholm Stock Exchange. It employs 83100 people.Things to note about AstraZeneca PLC performance evaluation
Checking the ongoing alerts about AstraZeneca PLC for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AstraZeneca PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AstraZeneca PLC has accumulated 22.96 B in total debt with debt to equity ratio (D/E) of 0.87, which is about average as compared to similar companies. AstraZeneca PLC has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist AstraZeneca PLC until it has trouble settling it off, either with new capital or with free cash flow. So, AstraZeneca PLC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AstraZeneca PLC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AstraZeneca to invest in growth at high rates of return. When we think about AstraZeneca PLC's use of debt, we should always consider it together with cash and equity. |
- Analyzing AstraZeneca PLC's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AstraZeneca PLC's stock is overvalued or undervalued compared to its peers.
- Examining AstraZeneca PLC's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AstraZeneca PLC's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AstraZeneca PLC's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AstraZeneca PLC's stock. These opinions can provide insight into AstraZeneca PLC's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for AstraZeneca Stock Analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.